Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5635 in Healthy Subjects and Chronic Hepatitis B Patients
NCT05808374Phase 1Unknown
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- May 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-5635 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Number of Adverse Events In Part 1 at 85 days and Number of Adverse Events In Part 2 at 169 days. Status: unknown.
02
Drugs
HRS-5635
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05808374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808374.